Industry payments to hospitalist physicians: a 5‐year analysis of the Open Payments programme from 2014 to 2018
| Autor: | Sreenath Meegada, Sen Sheng, Praveen Bere, Sisira Yadala, Akshay Avula, Vaishali Thombre, Suman Siddamreddy, Karthika Veerapaneni, Krishna Nalleballe, Vasuki Dandu, Nidhi Kapoor, Krishna Chaitanya Pakanati |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Health economics Drug Industry Conflict of Interest business.industry media_common.quotation_subject 030204 cardiovascular system & hematology Payment United States 03 medical and health sciences 0302 clinical medicine Hospitalists Family medicine Internal Medicine medicine Humans Industry Apixaban 030212 general & internal medicine business media_common medicine.drug |
| Zdroj: | Internal Medicine Journal. 50:1547-1550 |
| ISSN: | 1445-5994 1444-0903 |
| Popis: | We analysed Open Payments programme data (https://openpaymentsdata.cms.gov) on industry-to-physician payments to hospitalists for the years 2014 to 2018. Payments to hospitalists increased by 106.5% from 2014 to 2018 with food and beverage (38.5%) and compensation for services other than consulting (24.3%) being the highest-paid categories. Industry payment to hospitalists was highly skewed with top 10 hospitalists receiving more than 30% of the total payments during the study period. The most common drugs associated with payments were anticoagulant medications (apixaban and rivaroxaban). Industry seems to be spending a significant amount of money to increase awareness of medications among hospitalists. Identification of these trends and potential motives of industry spending is critical to address any potential physician bias. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text